F-1: Altamira Therapeutics Seeks to Register 2 Million Common Shares for Resale by Lincoln Park Capital

Altamira Therapeutics has filed a registration statement for the resale of up to 2,000,000 common shares by Lincoln Park Capital Fund, LLC.

Summary

• Altamira Therapeutics Ltd. has filed a registration statement with the SEC to allow Lincoln Park Capital Fund, LLC (LPC) to resell up to 2,000,000 common shares.
• These shares may be issued and sold to LPC under a purchase agreement dated December 5, 2022.
• Altamira may receive up to $8,814,200 from the sale of these shares to LPC, but will not receive any proceeds from LPC's resale of the shares.
• As of April 5, 2024, Altamira had 2,240,245 common shares outstanding.
• The company intends to use any net proceeds from the sales to LPC for working capital and general corporate purposes.
• LPC is considered an underwriter and may sell the shares in various ways at varying prices.
• Altamira will pay the expenses for registering the shares.
• The company's common shares are currently traded on the Nasdaq Capital Market under the symbol CYTO.
• The closing price on April 5, 2024, was $1.975 per share.
• Altamira is a foreign private issuer and is subject to reduced public company reporting requirements.
• Investing in Altamira's common shares involves a high degree of risk.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company gains access to potential funding, it comes with the risk of dilution and reliance on a single investor. The company's control over the timing of sales is a positive aspect.

Positives

• Altamira has the potential to raise up to $8,814,200 through sales of common shares to LPC.
• The company retains control over the timing and amount of sales to LPC.
• The funds raised can be used for working capital and general corporate purposes, providing financial flexibility.
• LPC is obligated to make purchases of common shares as Altamira may properly direct LPC to purchase, upon the terms and subject to the satisfaction of the conditions set forth therein.

Negatives

• Altamira will not receive any proceeds from the resale of shares by LPC.
• The market price of Altamira's common shares may fluctuate, affecting the actual proceeds received.
• The issuance of additional shares will dilute the ownership interest of existing shareholders.
• The company is dependent on LPC to make purchases of common shares as Altamira may properly direct LPC to purchase, upon the terms and subject to the satisfaction of the conditions set forth therein.

Risks

• Investing in Altamira's common shares involves a high degree of risk.
• The actual number of shares sold and the gross proceeds are unpredictable.
• Shareholders may experience dilution.
• Management has broad discretion over the use of proceeds, which may not yield favorable returns.
• The company's success depends on preclinical programs like OligoPhore, SemaPhore, AM-401, and AM-411.
• The company may be exposed to liability claims from clinical testing.
• Clinical trials may be delayed or unsuccessful.
• The company relies on third parties for studies and key ingredients.
• The company's intellectual property rights may be infringed.
• The company may not meet Nasdaq's listing requirements.
• Intangible assets may be impaired.

Future Outlook

Altamira expects that any net proceeds received from such sales to LPC under the Purchase Agreement will be used for working capital and general corporate purposes.

Industry Context

This announcement reflects a common financing strategy for development-stage biopharmaceutical companies, utilizing equity lines of credit to secure funding for ongoing operations and research. Similar arrangements are often seen with other small-cap biotech firms seeking capital to advance their pipelines.

Comparison to Industry Standards

• Comparable companies, such as those in the Russell Microcap Index, often utilize similar financing mechanisms like equity lines of credit.
• The terms of the Purchase Agreement, including the Beneficial Ownership Limitation of 4.99%, are standard in these types of arrangements to prevent LPC from gaining significant control of the company.
• The potential dilution impact of up to 47.2% of outstanding shares is significant but not uncommon for companies relying on equity financing.

Related Party Transactions

• The Purchase Agreement and Registration Rights Agreement with Lincoln Park Capital Fund, LLC constitute related party transactions.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interest.
• The company's employees and operations may benefit from the additional working capital.
• The company's creditors may benefit from the improved financial stability.

Next Steps

• The SEC must declare the registration statement effective.
• Altamira may then elect to sell common shares to LPC under the Purchase Agreement.
• LPC may resell the registered shares from time to time.
• Altamira may need to file additional registration statements if it wishes to sell more than 2,000,000 shares to LPC.

Key Dates

Keywords

common shares, Lincoln Park Capital, resale, registration statement, equity financing, dilution, CYTO, Altamira Therapeutics, securities, shares